BioMarin exceeded Q4 earnings expectations, raised 2025 guidance, and projected strong Voxzogo growth. Analysts increased price targets following the results.

Q4 2024 Earnings Call Transcript February 19, 2025 BioMarin Pharmaceutical Inc. beats earnings expectations. Reported EPS is $0.64, expectations were $0.54. Operator: Ladies and gentlemen, thank you ...

These useful findings assigned a novel functional implication of histone acylation, crotonylation. Although the mechanistic insights have been provided in great detail regarding the role of the YEATS2 ...